World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   254 records for 37 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4
Recruitment statusMain ID Public TitleDate of Registration
RecruitingNCT02156804
A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2014-001286-28-ATA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.06/08/2014
AuthorisedEUCTR2014-001286-28-BEA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.23/07/2014
AuthorisedEUCTR2014-001286-28-ESA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.06/08/2014
AuthorisedEUCTR2014-001286-28-DEA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.01/08/2014
AuthorisedEUCTR2014-001286-28-NLA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.06/08/2014
AuthorisedEUCTR2014-001286-28-PTA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.29/08/2014
AuthorisedEUCTR2014-001286-28-SEA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.30/09/2014
AuthorisedEUCTR2014-001286-28-FIA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.17/10/2014
AuthorisedEUCTR2014-001286-28-DKA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.13/08/2014
AuthorisedEUCTR2014-001286-28-ITA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.31/07/2014
AuthorisedEUCTR2014-001286-28-IEA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.11/09/2014
RecruitingDRKS00006730A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody08/12/2014
AuthorisedEUCTR2014-001286-28-HUA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.29/12/2014
AuthorisedEUCTR2014-001286-28-GRA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.08/05/2015
AuthorisedEUCTR2014-001286-28-GBA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.04/08/2014
29/05/2014
Not recruitingNCT02150603
Patient-Reported Outcomes in Adults With Congenital Heart Disease
21/05/2014
Not recruitingNCT01878760
APRICOT: Anaesthesia PRactice In Children Observational Trial
28/05/2013
Not recruitingNCT01694745
EUROpean Pain Audit In Neonates
25/09/2012
RecruitingNCT01667081
Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2012-002232-85-ITA Long-Term Follow-up Study to Evaluate Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial.19/10/2012
AuthorisedEUCTR2012-002232-85-ESA Long-Term Follow-up Study to Evaluate Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial25/02/2014
AuthorisedEUCTR2012-002232-85-GBA Long-Term Follow-up Study looking at the Virologic Response (checking a patient's blood to ensure that there is no detectable virus) and/or Viral Resistance (checking that the virus has not changed in anyway which might mean that treatment is no longer effective) of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial24/06/2013
AuthorisedEUCTR2012-002232-85-SEA Long-Term Follow-up Study to Evaluate Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial21/05/2013
AuthorisedEUCTR2012-002232-85-LTA Long-Term Follow-up Study to Evaluate Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial16/01/2015
AuthorisedEUCTR2012-002232-85-EEA Long-Term Follow-up Study to Evaluate Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial03/02/2015
AuthorisedEUCTR2012-002232-85-FIA Long-Term Follow-up Study to Evaluate Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial29/12/2014
AuthorisedEUCTR2012-002232-85-NLMK-5172 Protocol 017 Long-term Follow Up Study08/01/2015
AuthorisedEUCTR2012-002232-85-ATMK-5172 Protocol 017 Long-term Follow Up Study30/03/2015
AuthorisedEUCTR2012-002232-85-HUA Long-Term Follow-up Study to Evaluate Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial06/02/2014
AuthorisedEUCTR2012-002232-85-DEA Long-Term Follow-up Study to Evaluate Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial12/09/2012
14/08/2012
AuthorisedEUCTR2010-023526-21-ES
Estudio multicéntrico, abierto, de acceso expandido, de RO5185426 en pacientes con melanoma metastásico An open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2010-023526-21-SIAn open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma 18/01/2011
AuthorisedEUCTR2010-023526-21-GRAn open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma 21/01/2011
AuthorisedEUCTR2010-023526-21-HUAn open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma 04/02/2011
AuthorisedEUCTR2010-023526-21-NLAn open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma 11/01/2011
AuthorisedEUCTR2010-023526-21-ITAn open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma. - ND12/05/2011
AuthorisedEUCTR2010-023526-21-PTAn open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma 27/04/2011
AuthorisedEUCTR2010-023526-21-LVAn open-label, multicenter study to assess the safety of RO5185426 in patients with metastatic melanoma02/05/2011
AuthorisedEUCTR2010-023526-21-ATAn open-label, multicenter study to assess the safety of RO5185426 in patients with metastatic melanoma21/12/2010
AuthorisedEUCTR2010-023526-21-CZAn open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma 04/02/2011
AuthorisedEUCTR2010-023526-21-SEAn open-label, multicenter study to assess the safety of RO5185426 in patients with metastatic melanoma23/12/2010
AuthorisedEUCTR2010-023526-21-BEAn open-label, multicenter study to assess the safety of RO5185426 in patients with metastatic melanoma17/02/2011
AuthorisedEUCTR2010-023526-21-GBAn open-label, multicenter study to assess the safety of RO5185426 in patients with metastatic melanoma04/02/2011
AuthorisedEUCTR2010-023526-21-EEAn open-label, multicenter study to assess the safety of RO5185426 in patients with metastatic melanoma13/09/2011
AuthorisedEUCTR2010-023526-21-LTAn open-label, multicenter study to assess the safety of RO5185426 in patients with metastatic melanoma27/09/2011
AuthorisedEUCTR2010-023526-21-BGAn open-label, multicenter study to assess the safety of RO5185426 in patients with metastatic melanoma24/02/2011
AuthorisedEUCTR2010-023526-21-NOAn open-label, multicenter study to assess the safety of RO5185426 in patients with metastatic melanoma28/02/2011
AuthorisedEUCTR2010-023526-21-DEAn open-label, multicenter study to assess the safety of RO5185426 in patients with metastatic melanoma 26/01/2011
AuthorisedEUCTR2010-023526-21-IEAn open-label, multicenter study to assess the safety of RO5185426 in patients with metastatic melanoma 06/10/2011
Not RecruitingEUCTR2010-023526-21-DKAn open-label, multicenter study to assess the safety of RO5185426 in patients with metastatic melanoma05/09/2011
Not RecruitingDRKS00003620An Open-label, Multicenter Study to Assess the Safety of RO5185426 in Patients With Metastatic Melanoma29/03/2012
Not recruitingNCT01307397A Study of RO5185426 in Patients With Metastatic Melanoma17/02/2011
Not RecruitingCTRI/2012/07/002756Clinical Trial for metastatic melanoma patients. (skin cancer)02-07-2012
Not RecruitingEUCTR2010-023526-21-FIAn open-label, multicenter study of RO5185426 in patients with metastatic melanoma 12/05/2011
17/12/2010
Not recruitingNCT01261273
e-NOBORI Observational Registry of Nobori DES
14/12/2010
Not recruitingNCT01203605
European Surgical Outcomes Study
15/09/2010
Not recruitingNCT00990964
Attain Success Clinical Trial
Recruitment statusMain IDPublic titleDate of registration
Not RecruitingCTRI/2009/091/001072Attain Success Trial : a clinical trial to assess left-heart lead implant success and complication rate using the Medtronic leads and delivery catheters15-04-2010
06/10/2009
Not recruitingNCT00925600
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2009-012076-26-FRA Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects with Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss due to Androgen-Deprivation Therapy06/08/2009
AuthorisedEUCTR2009-012076-26-GRA Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects with Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss due to Androgen-Deprivation Therapy22/10/2009
AuthorisedEUCTR2009-012076-26-LVA Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy16/10/2009
AuthorisedEUCTR2009-012076-26-HUA Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy24/11/2010
AuthorisedEUCTR2009-012076-26-BGA Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy11/06/2010
AuthorisedEUCTR2009-012076-26-SIA Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy18/01/2011
AuthorisedEUCTR2009-012076-26-PLA Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy22/09/2009
AuthorisedEUCTR2009-012076-26-CZA Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy10/08/2009
RecruitingCTRI/2012/08/002905A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects with Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss due to Androgen-Deprivation Therapy23-08-2012
18/06/2009
    
1 2 3 4
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.2 - Version history